8x8 Named in Tech Titans Report as Top UK Public Sector Tech Supplier
The latest Tech Titans report by data insights company Tussell and digital trade association techUK highlights vendors helping government bodies unify systems, reduce complexity, and deliver better outcomes. 8x8 stands out for its role in enabling this shift through the 8x8 Platform for CX – the industry's most integrated customer experience platform, combining Contact Center, Unified Communications, and CPaaS in a single solution.
According to the report, the top 150 suppliers – just 2 percent of the market – captured 84 percent of the UK's £19.6 billion public sector tech spend, underscoring the growing demand for trusted, scalable platforms like 8x8.
Public Sector Tech Spend Hits Record High - and Set to Continue
The findings, curated from Tussell's database of government contracts and invoices, show spending surged across central government, healthcare, and national security sectors, while only local government saw a modest decline. The spending is set to continue with at least £28.2bn of Tech Titan contracts set to be renewed or bid for by July 2029.
Organizations need to make the right call
'Between the PSTN switch-off in early 2027, AI demands, and legacy systems past their sell-by date, the stakes have never been higher,' said Jamie Snaddon, GVP, Managing Director of EMEA at 8x8, Inc. 'Public sector teams can't afford - in any sense of the word - to get it wrong. We're helping them cut through complexity, unify communication, and serve faster.'
The Changing Nature of Public Sector Spending
The Tussell report shows the shifting face of spending and needs across the public sector, revealing:
IT Resellers Lead Growth: IT resellers saw the highest growth among supplier types, with a 77% increase in direct public sector revenue over four years
Central Government + NHS Drive Investment: These two verticals showed the strongest spend growth
Missed Frameworks = Missed Revenue: Suppliers lost out on £11.4 billion in public sector opportunities by not being listed on the right frameworks.
The Public Sector Is Shifting from Custom to Configured: The dominance of resellers and modular platforms reflects a broader trend: buyers now favor scalable, low-friction tech over complex, bespoke implementations.
Trusted by Government, Built for What's Next
8x8 has a strong history of providing services and expertise across the UK public sector, including Oldham Council, London Borough of Barking & Dagenham, and many more with a range of tools including The 8x8 Platform for CX and Ballot It, the election assistant tool.
8x8: Supporting Public Sector Modernization
8x8 provides an AI-enabled platform that brings together contact center, unified communications, and CPaaS capabilities. Public sector organizations — from government departments to NHS trusts — are using it to streamline communication, reduce system fragmentation, and improve service coordination.
Download the Report
The full report can be found on the Tussell website.
About 8x8 Inc.
8x8, Inc. (NASDAQ: EGHT) connects people and organizations through seamless communication on the industry's most integrated platform for Customer Experience – combining Contact Center, Unified Communication, and CPaaS solutions. The 8x8® Platform for CX integrates AI at every level to enable personalized customer journeys, drive operational excellence and insights, and facilitate team collaboration. We help customer experience and IT leaders become the heartbeat of their organizations, empowering them to unlock the potential of every interaction. For additional information, visit www.8x8.com, or follow 8x8 on LinkedIn, X, and Facebook.
Copyright 8x8, Inc. 8x8® is a trademark of 8x8, Inc. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
42 minutes ago
- Business Wire
Krispy Kreme Appoints Raphael Duvivier as Chief Financial Officer
CHARLOTTE, N.C.--(BUSINESS WIRE)--Krispy Kreme, Inc. (NASDAQ: DNUT) ('Krispy Kreme' or the 'Company') today announced that Raphael Duvivier, President, International of Krispy Kreme, has been named Chief Financial Officer, effective July 11, 2025. Mr. Duvivier succeeds Jeremiah Ashukian, who decided to leave the Company to pursue an opportunity with a private company. Since joining Krispy Kreme in 2019, Mr. Duvivier has held multiple leadership roles at the Company, including segment Chief Financial and Strategy Officer, International, and Chief Development Officer, leading international development, strategy, finance, and operations. He previously held various senior leadership positions in global finance, development, and operations at Restaurant Brands International Inc. (NYSE: QSR). Prior to that, he held leadership positions at Opus Investimentos. Mr. Duvivier has over 20 years of global experience across finance, strategy, and operations. 'Raphael has been a respected leader at Krispy Kreme for over six years, and his deep understanding of the Company coupled with his strong finance background will enable a smooth transition as we focus on achieving sustainable, profitable growth,' said Josh Charlesworth, Krispy Kreme CEO. 'I am excited to partner even more closely with Raphael and believe his experience, expertise, and leadership style will be a huge benefit as he assumes the role of Chief Financial Officer.' Additionally, Chief Product Officer Alison Holder has been promoted to Chief Brand and Product Officer effective July 11, 2025, assuming responsibility for the Company's global marketing initiatives. Ms. Holder has over 25 years of experience with Krispy Kreme, including as Senior Director of Consumer Insights, and has led brand marketing, innovation, research & development, and manufacturing services. She succeeds Chief Growth Officer David Skena who decided to leave the Company to pursue another opportunity. 'We thank Jeremiah and Dave for their contributions over the last several years and wish them both well in their new endeavors,' added Mr. Charlesworth. 'I have the utmost confidence in Raphael, Alison, and the rest of our strong team to help drive Krispy Kreme forward as we pursue U.S. expansion through high-volume retail points of distribution and capital-light international franchise growth.' About Krispy Kreme Headquartered in Charlotte, N.C., Krispy Kreme is one of the most beloved and well-known sweet treat brands in the world. Our iconic Original Glazed® doughnut is universally recognized for its hot-off-the-line, melt-in-your-mouth experience. Krispy Kreme operates in more than 40 countries through its unique network of fresh doughnut shops, partnerships with leading retailers, and a rapidly growing digital business. Our purpose of touching and enhancing lives through the joy that is Krispy Kreme guides how we operate every day and is reflected in the love we have for our people, our communities, and the planet. Connect with Krispy Kreme Doughnuts at and follow us on social: X, Instagram and Facebook.
Business Wire
an hour ago
- Business Wire
Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2025 on Wednesday, August 6, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 6, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the call via telephone from within the United States and Canada, dial +1 (833) 470-1428. From outside the United States and Canada, dial +1 (404) 975-4839. The access code for the call will be 015103. Replays of the call will be made available via telephone and webcast. A replay of the webcast will be posted on approximately one hour after the completion of the call and will remain available for one year. The telephonic replay will also be available approximately one hour after the completion of the call and will remain available for 7 days. To access the telephonic replay from within the United States and Canada, dial +1 (866) 813-9403. From outside the United States, dial +1 (929) 458-6194. The access code for the replay is 676245. Please check the website for updates regarding the timing of the live webcasts and for replay information. About Cencora Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. Cencora partners with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on Cencora for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Cencora's 51,000+ worldwide team members contribute to positive health outcomes through the power of Cencora's purpose: Cencora is united in its responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500 with more than $290 billion in annual revenue. Learn more at
Business Wire
2 hours ago
- Business Wire
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 175,000 shares of the company's common stock to one new employee (the 'Inducement Grant') on July 1, 2025 (the 'Grant Date'). The Inducement Grant has been granted outside of the company's Amended and Restated 2016 Equity Incentive Plan (the 'Plan') but remains subject to the terms and conditions of such Plan. The Inducement Grant was granted as an inducement material to the individual entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grant has an exercise price per share that is equal to the closing price of Viridian's common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee's start date, and thereafter the remainder of the shares vest in 36 equal monthly installments, subject to the employee's continued employment with Viridian through the applicable vesting dates. About Viridian Therapeutics Viridian is a biopharmaceutical company focused on discovering, developing and commercializing potential best-in-class medicines for patients with serious and rare diseases. Viridian's expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for veligrotug (VRDN-001), including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Both THRIVE and THRIVE-2 reported positive topline data, meeting all the primary and secondary endpoints of each study. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases. Viridian is based in Waltham, Massachusetts. For more information, please visit Follow Viridian on LinkedIn and X.
